Collegium Pharmaceutical
COLL
49 hedge funds and large institutions have $227M invested in Collegium Pharmaceutical in 2015 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 10 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
70% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 10
37% more capital invested
Capital invested by funds: $165M → $227M (+$61M)
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
7% more funds holding
Funds holding: 46 → 49 (+3)
Top Buyers
Top Sellers
COLL Hedge Fund Activity: Q3 2015 in Review
49 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q3 2015, worth a combined $227M — up 37% from $165M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new COLL positions and 10 closed out — a net gain of 3 holders — while 17 added to existing stakes and 10 trimmed.
The largest buyer was HealthCor Management, adding an estimated $8.61M. The largest seller was Broadfin Capital, exiting entirely with an estimated $5.3M sold.
- 49 institutional investors held Collegium Pharmaceutical (COLL) as of Q3 2015, up from 46 in Q2 2015.
- Funds reported $227M of Collegium Pharmaceutical stock for Q3 2015, up 37% quarter-over-quarter.
- 13 funds opened new Collegium Pharmaceutical positions in Q3 2015 and 10 closed out, a net change of +3 holders.
- The largest Collegium Pharmaceutical buyer in Q3 2015 was HealthCor Management, an estimated $8.61M added.
- The largest Collegium Pharmaceutical seller in Q3 2015 was Broadfin Capital, an estimated $5.3M sold.
Based on aggregated 13F filings for Q3 2015.